Invisicare is the core technology in Skinvisible’s portfolio of products. Skinvisible licenses it products on an exclusive basis to companies seeking new products in the areas such as acne, dermatitis, actinic keratosis, anti-inflammatories, analgesics and antimicrobials.
Skinvisible Pharma said that a total of 20 claims have been granted in the Korean patent which protects Invisicare in the areas of ‘Topical Composition,’ ‘Topical Composition Precursor,’ and ‘Methods for Manufacturing and Using.’
Terry Howlett, president and CEO of Skinvisible Pharma, said: “This latest patent strengthens the Company’s growing proprietary position internationally, allowing us to present patent-protected opportunities to global pharmaceutical and consumer goods companies.
“It also offers growing validation of the value of our technology as this patent, along with our other international patents, offers coverage of not only the composition, but also the manufacturing process and the dermatology indications our Invisicare technology is used for.”